mitozolomide mitozolomide mitozolomide (inn) is an antineoplastic. it is an imidazotetrazine derivative. mitozolomideclinical dataatc codenoneidentifiers iupac name 3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazotetrazine-8-carboxamide cas number85622-95-3 ypubchem cid71766chemspider64805 nuniie3u7286v3wchemblchembl435951 ncomptox dashboard (epa)dtxsid40234862 echa infocard100.079.921 chemical and physical dataformulac7h7cln6o2molar mass242.62 g·mol−13d model (jsmol)interactive image smiles nc(=o)c1ncn2c(=o)n(cccl)\n=n/c12 inchi inchi=1s/c7h7cln6o2/c8-1-2-14-7(16)13-3-10-4(5(9)15)6(13)11-12-14/h3h,1-2h2,(h2,9,15) nkey:qxyyypfgtsjxns-uhfffaoysa-n n ny (what is this?) (verify) development of mitozolomide was discontinued during phase ii clinical trials after it was found to cause severe and unpredictable bone marrow suppression. temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.